Table 1.
n.samples | IDScreen SARS-CoV-2N IgGIndirect Multispecies Conjugate | ERADIKIT™ COVID19-Multispecies | Double-Antigen N ELISA IZSLER | Wantai SARS-CoV-2 Ab ELISA | GenScript Surrogate VNT | Proteogenix SARS-CoV-2 Surrogate VNT | VNT (Rijkers et al., 2020) |
---|---|---|---|---|---|---|---|
CUT-Off | S/P% ≥ 40 | S/P% ≥ 20 | S/P% ≥ 10 | OD > 1000 | % Inhibition > 30 | % Inhibition | VNT50 ≥ 1/10 |
1 | <0.3 | 8.0 | 11.4 | 4549 | 95 | 0 | 1/80 |
2 | <0.3 | 100.3 | 40.5 | 4257 | 96 | 0 | 1/80 |
3 | <0.3 | 200.7 | 37.2 | 4923 | 96 | 6 | 1/160 |
4 | <0.3 | 287.9 | 107.0 | 4584 | 95 | 0 | 1/160 |
5 | <0.3 | 155.2 | 73.6 | 4051 | 96 | 0 | 1/160 |
6 | <0.3 | NT | NT | 4217 | 95 | NT | 1/160 |
7 | <0.3 | 39.7 | 28.1 | 4209 | 96 | 1 | 1/160 |
8 | <0.3 | 120.2 | 64.5 | 4157 | 96 | 0 | 1/80 |
9 | <0.3 | 190.9 | 61.2 | 3481 | 78 | 0 | 1/80 |
10 | <0.3 | 125.3 | 57.4 | 4171 | 95 | 10 | 1/80 |
11 | <0.3 | 103.7 | 36.0 | 4305 | 95 | 0 | 1/40 |
12 | <0.3 | 247.8 | 64.2 | 4104 | 94 | 23 | 1/160 |
13 | <0.3 | 279.3 | 83.5 | 4462 | 95 | 0 | 1/320 |
14 | <0.3 | 17.0 | 14.6 | 4310 | 48 | 0 | 1/10 |
15 | <0.3 | NT | 114.4 | 4438 | 95 | NT | 1/40 |
16 | <0.3 | 167.0 | 49.5 | 4500 | 95 | 0 | 1/80 |
17 | <0.3 | 106.5 | 35.9 | 5064 | 96 | 0 | 1/80 |
18 | <0.3 | 51.6 | 23.1 | 4416 | 95 | 0 | 1/160 |
19 | <0.3 | 108.3 | 38.0 | 4365 | 96 | 0 | 160 |
20 | <0.3 | 160.0 | 43.2 | 4247 | 95 | 0 | 1/160 |
21 | <0.3 | 17.7 | 2.2 | 4954 | 81 | 0 | 1/40 |
22 | <0.3 | 270.5 | 47.1 | 4688 | 78 | 0 | 1/10 |
23 | <0.3 | 292.4 | 87.1 | 6068 | 96 | 16 | 1/160 |
24 | <0.3 | 194.8 | 69.1 | 4415 | 49 | 0 | 1/10 |
25 | <0.3 | 210.6 | 57.2 | 5290 | 96 | 0 | 1/160 |
26 | <0.3 | 93.0 | 73.6 | 4512 | 94 | 0 | 1/160 |
27 | <0.3 | 39.4 | 73.3 | 5027 | 96 | 0 | 1/80 |
28 | <0.3 | 94.0 | 33.8 | 5165 | 94 | 0 | 1/160 |
29 | <0.3 | 177.2 | 53.6 | 6016 | 91 | 0 | 1/80 |
30 | <0.3 | 178.3 | 44.2 | 4840 | 96 | 0 | 1/80 |
31 | <0.3 | 8.8 | 15.1 | 4694 | 94 | 0 | 1/80 |
32 | <0.3 | 33.0 | 18.2 | 4472 | 96 | 0 | 1/160 |
33 | <0.3 | 14.4 | 0.21 | 4870 | 67 | 0 | 1/10 |
34 | <0.3 | 3.1 | 0.2 | 5171 | 95 | 0 | 1/80 |
35 | <0.3 | 99.1 | 27.0 | 5171 | 89 | 0 | 1/40 |
36 | <0.3 | 137.9 | 50.2 | 4460 | 89 | 0 | 1/160 |
37 | <0.3 | 27.4 | 6.12 | 4419 | 44 | 0 | 1/10 |
39 | <0.3 | NT | NT | 4875 | 95 | NT | 1/160 |
40 | <0.3 | 135.4 | 24.3 | 5419 | 95 | 0 | 1/80 |
41 | <0.3 | 1.8 | 12.2 | 6021 | 95 | 3 | 1/160 |
42 | <0.3 | 54.5 | 4 | 4817 | 95 | 0 | 1/40 |
43 | <0.3 | 238.4 | 96.5 | 5118 | 95 | 0 | 1/80 |
45 | <0.3 | 45.7 | 17.4 | 4907 | 96 | 6 | 1/40 |
46 | <0.3 | 277.1 | 112.5 | 4845 | 95 | 11 | 1/640 |
47 | <0.3 | 13.4 | 0.66 | 6068 | 80 | 0 | 1/40 |
48 | <0.3 | 234.1 | 65.3 | 5222 | 94 | 0 | 1/80 |
49 | <0.3 | 31.5 | 7.7 | 4892 | 94 | 0 | 1/80 |
50 | <0.3 | 38.8 | 17.4 | 4590 | 95 | 17 | 1/320 |
51 | <0.3 | 275.4 | 53 | 4687 | 95 | 0 | 1/160 |
52 | <0.3 | NT | NT | 4536 | 94 | NT | NT |
53 | <0.3 | 158.2 | 63.7 | 4477 | 94 | 0 | 1/80 |
54 | <0.3 | 26.8 | 14.8 | 4477 | 95 | 0 | 1/160 |
55 | <0.3 | 79.3 | 20.3 | 4521 | 96 | 11 | 1/160 |
56 | <0.3 | 164.9 | 90.8 | 4337 | 94 | 0 | 1/160 |
57 | <0.3 | 124.7 | 43.6 | 4932 | 95 | 0 | 1/640 |
58 | <0.3 | 23.3 | 15.3 | 5601 | 95 | 0 | 1/320 |
59 | <0.3 | NT | NT | 4615 | 94 | NT | 1/20 |
60 | <0.3 | 36.2 | 20.0 | 4716 | 88 | 0 | 1/40 |
61 | <0.3 | NT | NT | 6078 | 95 | NT | NT |
62 | <0.3 | 52.2 | 30.0 | 4902 | 95 | 0 | 1/160 |
63 | <0.3 | 142.7 | 44.2 | 4692 | 51 | 0 | 1/20 |
64 | <0.3 | 228.6 | 91.0 | 4838 | 96 | 0 | 1/160 |
65 | <0.3 | 64.1 | 15.1 | 4537 | 88 | 0 | 1/40 |
66 | <0.3 | 176.3 | 92.3 | 4509 | 95 | 0 | 1/160 |
67 | <0.3 | 26.0 | 19.5 | 4434 | 95 | 0 | 1/160 |
68 | <0.3 | 15.9 | 19.2 | 4201 | 94 | 0 | 1/80 |
69 | <0.3 | 84.1 | 25.2 | 4652 | 95 | 0 | 1/160 |
70 | <0.3 | 123.1 | 50.2 | 4236 | 95 | 0 | 1/160 |
71 | <0.3 | 29.5 | 13.5 | 4270 | 89 | 0 | 1/40 |
72 | <0.3 | 245.4 | 58.8 | 4115 | 94 | 0 | 1/80 |
73 | <0.3 | 115.2 | 86.9 | 3995 | 96 | 0 | 1/160 |
74 | <0.3 | NT | NT | 3999 | 89 | NT | 1/40 |
n.samples | IDScreen SARS-CoV-2N IgGIndirect Multispecies conjugate | ERADIKIT™ COVID19-Multispecies | Double-Antigen N ELISA IZSLER | Wantai SARS-CoV-2 Ab ELISA | GenScript Surrogate VNT | Proteogenix SARS-CoV-2 surrogate VNT | VNT (Rijkers et al., 2020) |
CUT-off | S/P% ≥ 40 | S/P% ≥ 20 | S/P% ≥ 10 | OD > 1000 | % inhibition > 30 | % inhibition | VNT50 ≥ 1/10 |
75 | <0.3 | 11.7 | 4.9 | 98 | 11 | NT | <1/5 |
76 | <0.3 | 12.6 | 3.8 | 83 | 0 | NT | <1/5 |
77 | <0.3 | 10.0 | 5 | 74 | 9 | NT | <1/5 |
78 | <0.3 | 13.8 | 4.6 | 77 | 9 | NT | <1/5 |
79 | <0.3 | 13.6 | 3.8 | 35 | 5 | NT | <1/5 |
80 | <0.3 | 6.0 | 4.1 | 87 | 0 | NT | <1/5 |
81 | <0.3 | 5.8 | 4.5 | 84 | 0 | NT | <1/5 |
82 | <0.3 | 6.8 | 4.3 | 159 | 2 | NT | <1/5 |
83 | <0.3 | 3.2 | 4.2 | 139 | 4 | NT | <1/5 |
84 | <0.3 | 8.6 | 4.5 | 109 | 0 | NT | <1/5 |
85 | <0.3 | 10.0 | 4.3 | 135 | 2 | NT | <1/5 |
86 | <0.3 | 13.1 | 4.7 | 39 | 5 | NT | <1/5 |
87 | <0.3 | 10 | 3.9 | 136 | 3 | NT | <1/5 |
88 | <0.3 | 4.2 | 6 | 137 | 5 | NT | <1/5 |
89 | <0.3 | 18.7 | 5.6 | 148 | 7 | NT | <1/5 |
90 | <0.3 | 8.1 | 5.2 | 216 | 3 | NT | <1/5 |
91 | <0.3 | 1.8 | 3.7 | 29 | 0 | NT | <1/5 |
92 | <0.3 | 5.5 | 4.2 | 68 | 6 | NT | <1/5 |
93 | <0.3 | 3.3 | 4.6 | 84 | 4 | NT | <1/5 |
94 | NT | 0.4 | 4 | 20 | 0 | NT | <1/5 |
95 | NT | 3 | 4.4 | 113 | 1 | NT | <1/5 |
96 | NT | 5.8 | 4.1 | 82 | 0 | NT | <1/5 |
97 | NT | 10 | 5.2 | 84 | 0 | NT | <1/5 |
98 | NT | 12 | 4.8 | 174 | 4 | NT | <1/5 |
99 | NT | 5 | 3.9 | 110 | 0 | NT | <1/5 |
100 | NT | 4.5 | 3.7 | 97 | 0 | NT | <1/5 |
101 | NT | 10.3 | 3.8 | 97 | 7 | NT | <1/5 |
102 | NT | 2.7 | 3.9 | 102 | 1 | NT | <1/5 |
103 | NT | 0.1 | 4 | 74 | 0 | NT | <1/5 |
104 | NT | 3.6 | 4.1 | 107 | 0 | NT | <1/5 |
105 | NT | 4.3 | 4.6 | 73 | 6 | NT | <1/5 |
106 | NT | 8.9 | 3.9 | 33 | 10 | NT | <1/5 |
107 | NT | 1.9 | 5.3 | 85 | 7 | NT | <1/5 |
108 | NT | 10.7 | 4.9 | 127 | 0 | NT | <1/5 |
109 | NT | 5.7 | 4.5 | 86 | 3 | NT | <1/5 |
110 | NT | 4.6 | 5.2 | 151 | 0 | NT | <1/5 |
111 | NT | 3 | 4.3 | 127 | 0 | NT | <1/5 |
112 | NT | 2.1 | 4.4 | 17 | 1 | NT | <1/5 |
113 | NT | 0.9 | 4.5 | 394 | 1 | NT | <1/5 |
114 | NT | 0.0 | 4.3 | 26 | 3 | NT | <1/5 |
115 | NT | 0.1 | 5.6 | 532 | 0 | NT | <1/5 |
116 | NT | 12.4 | 4.8 | 143 | 2 | NT | <1/5 |
117 | NT | 5.0 | 4.2 | 87 | 7 | NT | <1/5 |
118 | NT | 4.3 | 4.6 | 68 | 2 | NT | <1/5 |
Diagnostic test 2×2table | NT | Se: 86.15% (95%CI: 75.34–93.47) Sp: 100% (95%CI: 91.95–100) |
Se: 89.39% (95%CI: 75.36–95.63) Sp: 100% (95%CI: 91.95–100) |
Se: 100% (95%CI: 95–100) Sp: 100% (95%CI: 91.96–100) |
Se: 100% (95%CI: 95–100) Sp: 100% (95%CI: 91.96–100) |
NT | Se: 100% (95%CI: 94.87–100) Sp: 100% (95%CI: 91.96–100) |
K cohen agreement vs. VNT | NT | K: 0.83 (95%CI: 0.73–0.93) |
K: 0.87 (95%CI: 0.78–0.96) |
K: 1 (95%: +/−0) |
K: 1 (95%: +/−0) |
NT |